Résultats de recherche
Annie F. Luetkemeyer (born April 13, 1972, Baltimore, Maryland, U.S.) is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco.
Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED. PMID: 23676159. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Annie Luetkemeyer is a clinical professor of HIV, infectious disease, and global medicine at UCSF. She has expertise in HIV therapeutic strategies, COVID-19 treatment and prevention, and viral hepatitis.
Annie Luetkemeyer is a professor at the School of Medicine of the University of California, San Francisco. She studies the microbiome and its role in infectious diseases, such as hepatitis C, COVID-19, and tuberculosis.
Annie Luetkemeyer's 25 research works with 6,553 citations and 2,947 reads, including: Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
CFAR Awards. Comparison of Quantiferon to Conventional Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection (LTBI) in HIV Positive Subjects. Mentored Scientist Award, Spring 2005.
Annie Luetkemeyer, MD, is a UCSF infectious disease physician and researcher who leads clinical trials of promising therapies for COVID-19, including remdesivir and convalescent plasma. She also cares for HIV and hepatitis C patients and advocates for vulnerable populations affected by the pandemic.
